PT - JOURNAL ARTICLE AU - Hiroyuki Yamanaka AU - Miki Nakajima AU - Miki Katoh AU - Ayano Kanoh AU - Osamu Tamura AU - Hiroyuki Ishibashi AU - Tsuyoshi Yokoi TI - <em>TRANS</em>-3′-HYDROXYCOTININE <em>O</em>- AND <em>N</em>-GLUCURONIDATIONS IN HUMAN LIVER MICROSOMES AID - 10.1124/dmd.104.001701 DP - 2005 Jan 01 TA - Drug Metabolism and Disposition PG - 23--30 VI - 33 IP - 1 4099 - http://dmd.aspetjournals.org/content/33/1/23.short 4100 - http://dmd.aspetjournals.org/content/33/1/23.full SO - Drug Metab Dispos2005 Jan 01; 33 AB - Trans-3′-hydroxycotinine is a major metabolite of nicotine in humans and is mainly excreted as O-glucuronide in smoker's urine. Incubation of human liver microsomes with UDP-glucuronic acid produces not only trans-3′-hydroxycotinine O-glucuronide but also N-glucuronide. The formation of N-glucuronide exceeds the formation of O-glucuronide in most human liver microsomes, although N-glucuronide has never been detected in human urine. Trans-3′-hydroxycotinine N-glucuronidation in human liver microsomes was significantly correlated with nicotine and cotinine N-glucuronidations, which are catalyzed mainly by UDP-glucuronosyltransferase (UGT)1A4 and was inhibited by imipramine and nicotine, which are substrates of UGT1A4. Recombinant UGT1A4 exhibited substantial trans-3′-hydroxycotinine N-glucuronosyltransferase activity. These results suggest that trans-3′-hydroxycotinine N-glucuronidation in human liver microsomes would be mainly catalyzed by UGT1A4. In the present study, trans-3′-hydroxycotinine O-glucuronidation in human liver microsomes was thoroughly characterized, since trans-3′-hydroxycotinine O-glucuronide is one of the major metabolites of nicotine. The kinetics were fitted to the Michaelis-Menten equation with a Km of 10.0 ± 0.8 mM and a Vmax of 85.8 ± 3.8 pmol/min/mg. Among 11 recombinant human UGT isoforms expressed in baculovirus-infected insect cells, UGT2B7 exhibited the highest trans-3′-hydroxycotinine O-glucuronosyltransferase activity (1.1 pmol/min/mg) followed by UGT1A9 (0.3 pmol/min/mg), UGT2B15 (0.2 pmol/min/mg), and UGT2B4 (0.2 pmol/min/mg) at a substrate concentration of 1 mM. Trans-3′-hydroxycotinine O-glucuronosyltransferase activity by recombinant UGT2B7 increased with an increase in the substrate concentration up to 16 mM (10.5 pmol/min/mg). The kinetics by recombinant UGT1A9 were fitted to the Michaelis-Menten equation with Km = 1.6 ± 0.1 mM and Vmax = 0.69 ± 0.02 pmol/min/mg of protein. Trans-3′-hydroxycotinine O-glucuronosyltransferase activities in 13 human liver microsomes ranged from 2.4 to 12.6 pmol/min/mg and were significantly correlated with valproic acid glucuronidation (r = 0.716, p &lt; 0.01), which is catalyzed by UGT2B7, UGT1A6, and UGT1A9. Trans-3′-hydroxycotinine O-glucuronosyltransferase activity in human liver microsomes was inhibited by imipramine (a substrate of UGT1A4, IC50 = 55 μM), androstanediol (a substrate of UGT2B15, IC50 = 169 μM), and propofol (a substrate of UGT1A9, IC50 = 296 μM). Interestingly, imipramine (IC50 = 45 μM), androstanediol (IC50 = 21 μM), and propofol (IC50 = 41 μM) also inhibited trans-3′-hydroxycotinine O-glucuronosyltransferase activity by recombinant UGT2B7. These findings suggested that trans-3′-hydroxycotinine O-glucuronidation in human liver microsomes is catalyzed by mainly UGT2B7 and, to a minor extent, by UGT1A9. The American Society for Pharmacology and Experimental Therapeutics